1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Temsirolimus 1.2.3 Everolimus 1.3 Market by Application 1.3.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Hospital 1.3.3 Clinic 1.3.4 Drug Center 1.3.5 Other 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Perspective (2016-2027) 2.2 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Growth Trends by Regions 2.2.1 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Historic Market Share by Regions (2016-2021) 2.2.3 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Forecasted Market Size by Regions (2022-2027) 2.3 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Industry Dynamic 2.3.1 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Trends 2.3.2 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Drivers 2.3.3 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Challenges 2.3.4 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Players by Revenue 3.1.1 Global Top PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Players by Revenue (2016-2021) 3.1.2 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Players (2016-2021) 3.2 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue 3.4 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Concentration Ratio 3.4.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue in 2020 3.5 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Key Players Head office and Area Served 3.6 Key Players PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product Solution and Service 3.7 Date of Enter into PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market 3.8 Mergers & Acquisitions, Expansion Plans 4 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Breakdown Data by Type 4.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Historic Market Size by Type (2016-2021) 4.2 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Forecasted Market Size by Type (2022-2027) 5 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Breakdown Data by Application 5.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Historic Market Size by Application (2016-2021) 5.2 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size (2016-2027) 6.2 North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type 6.2.1 North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2016-2021) 6.2.2 North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2022-2027) 6.2.3 North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2016-2027) 6.3 North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application 6.3.1 North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2016-2021) 6.3.2 North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2022-2027) 6.3.3 North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2016-2027) 6.4 North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country 6.4.1 North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country (2016-2021) 6.4.2 North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country (2022-2027) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size (2016-2027) 7.2 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type 7.2.1 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2016-2021) 7.2.2 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2022-2027) 7.2.3 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2016-2027) 7.3 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application 7.3.1 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2016-2021) 7.3.2 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2022-2027) 7.3.3 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2016-2027) 7.4 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country 7.4.1 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country (2016-2021) 7.4.2 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size (2016-2027) 8.2 Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type 8.2.1 Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2016-2021) 8.2.2 Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2022-2027) 8.2.3 Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2016-2027) 8.3 Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application 8.3.1 Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2016-2021) 8.3.2 Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2022-2027) 8.3.3 Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2016-2027) 8.4 Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Region 8.4.1 Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Region (2016-2021) 8.4.2 Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size (2016-2027) 9.2 Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type 9.2.1 Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2016-2021) 9.2.2 Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2022-2027) 9.2.3 Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2016-2027) 9.3 Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application 9.3.1 Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2016-2021) 9.3.2 Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2022-2027) 9.3.3 Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2016-2027) 9.4 Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country 9.4.1 Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country (2016-2021) 9.4.2 Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size (2016-2027) 10.2 Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type 10.2.1 Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2016-2021) 10.2.2 Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2022-2027) 10.2.3 Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2016-2027) 10.3 Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application 10.3.1 Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2016-2021) 10.3.2 Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2022-2027) 10.3.3 Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2016-2027) 10.4 Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country 10.4.1 Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country (2016-2021) 10.4.2 Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Pfizer 11.1.1 Pfizer Company Details 11.1.2 Pfizer Business Overview 11.1.3 Pfizer PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction 11.1.4 Pfizer Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) 11.1.5 Pfizer Recent Development 11.2 Gland Pharma 11.2.1 Gland Pharma Company Details 11.2.2 Gland Pharma Business Overview 11.2.3 Gland Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction 11.2.4 Gland Pharma Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) 11.2.5 Gland Pharma Recent Development 11.3 Accord Healthcare 11.3.1 Accord Healthcare Company Details 11.3.2 Accord Healthcare Business Overview 11.3.3 Accord Healthcare PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction 11.3.4 Accord Healthcare Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) 11.3.5 Accord Healthcare Recent Development 11.4 Novartis 11.4.1 Novartis Company Details 11.4.2 Novartis Business Overview 11.4.3 Novartis PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction 11.4.4 Novartis Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) 11.4.5 Novartis Recent Development 11.5 Glenmark Pharmaceuticals 11.5.1 Glenmark Pharmaceuticals Company Details 11.5.2 Glenmark Pharmaceuticals Business Overview 11.5.3 Glenmark Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction 11.5.4 Glenmark Pharmaceuticals Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) 11.5.5 Glenmark Pharmaceuticals Recent Development 11.6 Cipla 11.6.1 Cipla Company Details 11.6.2 Cipla Business Overview 11.6.3 Cipla PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction 11.6.4 Cipla Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) 11.6.5 Cipla Recent Development 11.7 Dr Reddy's Laboratories 11.7.1 Dr Reddy's Laboratories Company Details 11.7.2 Dr Reddy's Laboratories Business Overview 11.7.3 Dr Reddy's Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction 11.7.4 Dr Reddy's Laboratories Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) 11.7.5 Dr Reddy's Laboratories Recent Development 11.8 Natco Pharma 11.8.1 Natco Pharma Company Details 11.8.2 Natco Pharma Business Overview 11.8.3 Natco Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction 11.8.4 Natco Pharma Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) 11.8.5 Natco Pharma Recent Development 11.9 Intas Pharmaceuticals 11.9.1 Intas Pharmaceuticals Company Details 11.9.2 Intas Pharmaceuticals Business Overview 11.9.3 Intas Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction 11.9.4 Intas Pharmaceuticals Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) 11.9.5 Intas Pharmaceuticals Recent Development 11.10 Panacea Biotec 11.10.1 Panacea Biotec Company Details 11.10.2 Panacea Biotec Business Overview 11.10.3 Panacea Biotec PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction 11.10.4 Panacea Biotec Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) 11.10.5 Panacea Biotec Recent Development 11.11 Alkem Laboratories 11.11.1 Alkem Laboratories Company Details 11.11.2 Alkem Laboratories Business Overview 11.11.3 Alkem Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction 11.11.4 Alkem Laboratories Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) 11.11.5 Alkem Laboratories Recent Development 11.12 Biocon Pharma 11.12.1 Biocon Pharma Company Details 11.12.2 Biocon Pharma Business Overview 11.12.3 Biocon Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction 11.12.4 Biocon Pharma Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) 11.12.5 Biocon Pharma Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Temsirolimus Table 3. Key Players of Everolimus Table 4. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 5. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 6. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Regions (2016-2021) & (US$ Million) Table 7. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Regions (2016-2021) Table 8. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 9. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Regions (2022-2027) Table 10. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Trends Table 11. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Drivers Table 12. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Challenges Table 13. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Restraints Table 14. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Players (2016-2021) & (US$ Million) Table 15. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Players (2016-2021) Table 16. Global Top PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer as of 2020) Table 17. Ranking of Global Top PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Companies by Revenue (US$ Million) in 2020 Table 18. Global 5 Largest Players Market Share by PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue (CR5 and HHI) & (2016-2021) Table 19. Key Players Headquarters and Area Served Table 20. Key Players PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product Solution and Service Table 21. Date of Enter into PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Table 22. Mergers & Acquisitions, Expansion Plans Table 23. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 24. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Type (2016-2021) Table 25. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Forecasted Market Size by Type (2022-2027) (US$ Million) Table 26. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Type (2022-2027) & (US$ Million) Table 27. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Share by Application (2016-2021) & (US$ Million) Table 28. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Application (2016-2021) Table 29. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Forecasted Market Size by Application (2022-2027) (US$ Million) Table 30. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Application (2022-2027) & (US$ Million) Table 31. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 32. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 33. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 34. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 35. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 36. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 37. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 38. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 39. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 40. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 41. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 42. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 43. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 44. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 45. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 46. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 47. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Region (2016-2021) & (US$ Million) Table 48. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Region (2022-2027) & (US$ Million) Table 49. Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 50. Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 51. Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 52. Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 53. Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 54. Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 55. Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2016-2021) (US$ Million) Table 56. Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2022-2027) & (US$ Million) Table 57. Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2016-2021) (US$ Million) Table 58. Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2022-2027) & (US$ Million) Table 59. Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 60. Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 61. Pfizer Company Details Table 62. Pfizer Business Overview Table 63. Pfizer PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product Table 64. Pfizer Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) & (US$ Million) Table 65. Pfizer Recent Development Table 66. Gland Pharma Company Details Table 67. Gland Pharma Business Overview Table 68. Gland Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product Table 69. Gland Pharma Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) & (US$ Million) Table 70. Gland Pharma Recent Development Table 71. Accord Healthcare Company Details Table 72. Accord Healthcare Business Overview Table 73. Accord Healthcare PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product Table 74. Accord Healthcare Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) & (US$ Million) Table 75. Accord Healthcare Recent Development Table 76. Novartis Company Details Table 77. Novartis Business Overview Table 78. Novartis PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product Table 79. Novartis Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) & (US$ Million) Table 80. Novartis Recent Development Table 81. Glenmark Pharmaceuticals Company Details Table 82. Glenmark Pharmaceuticals Business Overview Table 83. Glenmark Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product Table 84. Glenmark Pharmaceuticals Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) & (US$ Million) Table 85. Glenmark Pharmaceuticals Recent Development Table 86. Cipla Company Details Table 87. Cipla Business Overview Table 88. Cipla PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product Table 89. Cipla Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) & (US$ Million) Table 90. Cipla Recent Development Table 91. Dr Reddy's Laboratories Company Details Table 92. Dr Reddy's Laboratories Business Overview Table 93. Dr Reddy's Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product Table 94. Dr Reddy's Laboratories Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) & (US$ Million) Table 95. Dr Reddy's Laboratories Recent Development Table 96. Natco Pharma Company Details Table 97. Natco Pharma Business Overview Table 98. Natco Pharma Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) & (US$ Million) Table 99. Natco Pharma Recent Development Table 100. Intas Pharmaceuticals Company Details Table 101. Intas Pharmaceuticals Business Overview Table 102. Intas Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product Table 103. Intas Pharmaceuticals Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) & (US$ Million) Table 104. Intas Pharmaceuticals Recent Development Table 105. Panacea Biotec Company Details Table 106. Panacea Biotec Business Overview Table 107. Panacea Biotec PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product Table 108. Panacea Biotec Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) & (US$ Million) Table 109. Panacea Biotec Recent Development Table 110. Alkem Laboratories Company Details Table 111. Alkem Laboratories Business Overview Table 112. Alkem Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product Table 113. Alkem Laboratories Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) & (US$ Million) Table 114. Alkem Laboratories Recent Development Table 115. Biocon Pharma Company Details Table 116. Biocon Pharma Business Overview Table 117. Biocon Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product Table 118. Biocon Pharma Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) & (US$ Million) Table 119. Biocon Pharma Recent Development Table 120. Research Programs/Design for This Report Table 121. Key Data Information from Secondary Sources Table 122. Key Data Information from Primary Sources List of Figures Figure 1. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Type: 2020 VS 2027 Figure 2. Temsirolimus Features Figure 3. Everolimus Features Figure 4. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Application: 2020 VS 2027 Figure 5. Hospital Case Studies Figure 6. Clinic Case Studies Figure 7. Drug Center Case Studies Figure 8. Other Case Studies Figure 9. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Report Years Considered Figure 10. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 11. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 12. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Regions: 2020 VS 2027 Figure 13. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Regions (2022-2027) Figure 14. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Players in 2020 Figure 15. Global Top PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer as of 2020 Figure 16. The Top 10 and 5 Players Market Share by PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue in 2020 Figure 17. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Type (2016-2021) Figure 18. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by Type (2022-2027) Figure 19. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 20. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Type (2016-2027) Figure 21. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Application (2016-2027) Figure 22. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Country (2016-2027) Figure 23. United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 24. Canada PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 25. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 26. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Type (2016-2027) Figure 27. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Application (2016-2027) Figure 28. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Country (2016-2027) Figure 29. Germany PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 30. France PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 31. U.K. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 32. Italy PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 33. Russia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 34. Nordic PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Type (2016-2027) Figure 37. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Application (2016-2027) Figure 38. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Region (2016-2027) Figure 39. China PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 40. Japan PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 41. South Korea PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 42. Southeast Asia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 43. India PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 44. Australia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Type (2016-2027) Figure 47. Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Application (2016-2027) Figure 48. Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Country (2016-2027) Figure 49. Mexico PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 50. Brazil PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 51. Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 52. Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Type (2016-2027) Figure 53. Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Application (2016-2027) Figure 54. Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Country (2016-2027) Figure 55. Turkey PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 56. Saudi Arabia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 57. UAE PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size YoY Growth (2016-2027) & (US$ Million) Figure 58. Pfizer Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) Figure 59. Gland Pharma Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) Figure 60. Accord Healthcare Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) Figure 61. Novartis Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) Figure 62. Glenmark Pharmaceuticals Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) Figure 63. Cipla Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) Figure 64. Dr Reddy's Laboratories Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) Figure 65. Natco Pharma Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) Figure 66. Intas Pharmaceuticals Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) Figure 67. Panacea Biotec Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) Figure 68. Alkem Laboratories Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) Figure 69. Biocon Pharma Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2016-2021) Figure 70. Bottom-up and Top-down Approaches for This Report Figure 71. Data Triangulation Figure 72. Key Executives Interviewed

Pfizer Gland Pharma Accord Healthcare Novartis Glenmark Pharmaceuticals Cipla Dr Reddy's Laboratories Natco Pharma Intas Pharmaceuticals Panacea Biotec Alkem Laboratories Biocon Pharma